Want to see FR:ALAMA full AI Analyst Report?
Top Page
AMA Corporation Plc
(ALAMA)
Select Model
Select Model
Rating:42Neutral
Price Target:
€0.10
▼(-43.53% Downside)
Action:Reiterated
Date:10/07/26
The score is primarily pressured by weak financial performance (persistent losses, negative cash flow, and negative equity) and bearish technicals (price below major moving averages with negative MACD). Valuation offers limited support because the negative P/E reflects unprofitability and dividend yield data is unavailable.
Positive Factors
Strong gross margin
A strong gross margin indicates AMA retains meaningful economic value from its offerings before operating expenses. If maintained, this provides a foundation for future operating leverage, although the company must still reduce operating costs to convert that gross profit into sustainable earnings.
Negative Factors
Negative shareholders’ equity
Negative shareholders’ equity is a major solvency and financing risk because liabilities exceed the recorded asset base. It reduces the balance-sheet cushion available to absorb further losses and can constrain access to capital while increasing dependence on external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong gross margin
A strong gross margin indicates AMA retains meaningful economic value from its offerings before operating expenses. If maintained, this provides a foundation for future operating leverage, although the company must still reduce operating costs to convert that gross profit into sustainable earnings.
Read all positive factors
AMA Corporation Plc (ALAMA) vs. iShares MSCI France ETF (EWQ)
Market Cap
€5.30M
Dividend YieldN/A
Average Volume (3M)12.54K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth-20.28%
EPS Growth22.97%
CountryFR
Employees27
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.15
Shares Outstanding53,537,144
10 Day Avg. Volume6,618
30 Day Avg. Volume12,537
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-6.15
Price to Sales (P/S)3.07
P/FCF Ratio-1.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AMA Corporation Plc Business Overview & Revenue Model
Company Description
AMA Corporation Ltd delivers remote support solutions to industrial organizations, service providers, and medical institutions across the globe. The company develops its XpertEye assisted reality platform, which facilitates applications like remot...
How the Company Makes Money
null...
AMA Corporation Plc Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.99M | 2.49M | 3.01M | 4.28M | 6.57M |
| Gross Profit | 1.42M | 1.97M | -688.00K | 4.90M | 8.04M |
| EBITDA | -4.99M | -6.36M | -6.87M | -10.27M | -6.52M |
| Net Income | -5.67M | -7.34M | -8.04M | -21.39M | -9.84M |
Balance Sheet | |||||
| Total Assets | 4.43M | 9.17M | 12.75M | 13.65M | 38.22M |
| Cash, Cash Equivalents and Short-Term Investments | 2.09M | 5.82M | 9.39M | 8.60M | 20.64M |
| Total Debt | 2.79M | 4.03M | 3.96M | 4.53M | 4.70M |
| Total Liabilities | 5.37M | 6.62M | 6.97M | 7.85M | 11.32M |
| Stockholders Equity | -991.00K | 2.50M | 5.71M | 5.68M | 27.29M |
Cash Flow | |||||
| Free Cash Flow | -4.84M | -6.39M | -5.79M | -13.00M | -10.28M |
| Operating Cash Flow | -4.80M | -6.28M | -5.74M | -10.52M | -5.10M |
| Investing Cash Flow | 37.00K | 114.00K | 149.00K | -1.24M | -5.22M |
| Financing Cash Flow | 1.06M | 2.59M | 6.46M | -293.00K | 29.67M |
AMA Corporation Plc Technical Analysis
Negative
0.17
Price Trends
0.14
Negative
0.14
Negative
0.13
Negative
Market Momentum
-0.01
Negative
38.15
Neutral
76.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALAMA, the sentiment is Negative. The current price of 0.17 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.14, and above the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 38.15 is Neutral, neither overbought nor oversold. The STOCH value of 76.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALAMA.
AMA Corporation Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | €258.39M | 37.57 | 3.89% | ― | 6.28% | 204.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | €22.42M | -5.20 | -22.03% | ― | 37.28% | 7.83% | |
43 Neutral | €180.85M | -3.00 | 136.99% | ― | 2.16% | -5.26% | |
42 Neutral | €5.30M | -0.60 | ― | ― | -20.28% | 22.97% |
* Healthcare Sector Average
FR:ALAMA
AMA Corporation Plc
0.10
-0.07
-41.76%
FR:ALERS
Eurobio-Scientific SA
26.30
2.15
8.90%
FR:ALDMS
Diagnostic Medical Systems
0.91
-0.41
-30.95%
FR:ALIKO
Ikonisys SA
1.42
-0.04
-2.74%
FR:ALMDT
Median Technologies
3.69
0.79
27.24%
FR:ALBIO
Biosynex SA
0.84
0.23
37.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.